X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Rising Pharmaceuticals Demand Drives Tablet Coatings Market

    Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19

    Particle Size Distribution Real-Time Monitoring With PEACE

    Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

    Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

    Recipharm supports FDA approval of Perrigos AB-rated generic product

    FDA approves the manufacture of new microbiome-based therapeutic VOWSTTM at Recipharm site

    authorisation for roxadustat in China

    ABPI and NHS Are in Talks for New Medicines Scheme in the UK

    New Approach To Gene Editing For Improved Cancer Treatment

    Report Predicts OSD Contract Manufacturing Market Growth

    Driving Factors Behind Digital Bioprocessing Market Growth

    FDA Draft Guidance Supports Decentralized Clinical Trials

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Rising Pharmaceuticals Demand Drives Tablet Coatings Market

    Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19

    Particle Size Distribution Real-Time Monitoring With PEACE

    Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

    Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

    Recipharm supports FDA approval of Perrigos AB-rated generic product

    FDA approves the manufacture of new microbiome-based therapeutic VOWSTTM at Recipharm site

    authorisation for roxadustat in China

    ABPI and NHS Are in Talks for New Medicines Scheme in the UK

    New Approach To Gene Editing For Improved Cancer Treatment

    Report Predicts OSD Contract Manufacturing Market Growth

    Driving Factors Behind Digital Bioprocessing Market Growth

    FDA Draft Guidance Supports Decentralized Clinical Trials

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

European Medicines Agency Ends COVID-19 Prioritization Plan

Content Team by Content Team
13th May 2023
in News

The European Medicines Agency (EMA) and the European Medicines regulatory network have announced the lifting of COVID-19 business continuity measures, signifying a step towards normalizing regulatory processes as pandemic trends shift. These measures were introduced in 2020 to prioritize the assessment of COVID-19 therapeutics and vaccines, and as a part of this, COVID-19 medicines were given priority in various pharmacovigilance procedures.

Now, the EMA plans to systematically reinstate the activities and processes that were previously suspended or scaled back due to the pandemic. This gradual restoration of operations is a positive indication of progress towards resuming normal regulatory functions. Additionally, the EMA has set its sights on restarting the publication of clinical data for new active substances in the coming months.

The European medicines regulatory network has in it regulatory agencies from the member states of the European Economic Area. These member states encompass all the countries of the European Union, along with Iceland, Liechtenstein, and Norway, which are not EU members. This network brings together the regulatory authorities of these countries to collaborate and harmonize their efforts in overseeing the safety and efficacy of medicines within the EEA region.

In the global response to the COVID-19 pandemic, the recent announcement aligns with actions taken by the World Health Organization (WHO) and US authorities. President Joe Biden signed a resolution ending the COVID-19 national emergency, and the US Public Health Emergency ended on May 11. WHO’s Director-General, Tedros Adhanom Ghebreyesus, emphasized that while COVID-19 remains a health concern, it no longer holds the status of a public health emergency of international concern.

EMA’s Executive Director, Emer Cooke, sees this announcement as a major milestone and emphasizes that the agency will adapt its approach accordingly. Leveraging the lessons gained from the COVID-19 pandemic, the EMA aims to influence its strategy in various domains. In particular, it will concentrate on anti-cancer medicines this year to effectively apply the knowledge obtained. The European Medicines Agency’s programming document for 2025 highlights six critical areas of emphasis, demonstrating their commitment to ensuring the availability of medicines and addressing the risks posed by antimicrobial resistance and other emergencies.

Previous Post

Rising Pharmaceuticals Demand Drives Tablet Coatings Market

Related Posts

Drug Development

Rising Pharmaceuticals Demand Drives Tablet Coatings Market

13th May 2023
News

Connected Drug Delivery Devices To Revolutionize Healthcare

12th May 2023
Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19
Drug Development

Particle Size Distribution Real-Time Monitoring With PEACE

10th May 2023
Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity
Drug Development

Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

8th May 2023
Recipharm supports FDA approval of Perrigos AB-rated generic product
Drug Development

FDA approves the manufacture of new microbiome-based therapeutic VOWSTTM at Recipharm site

8th May 2023
authorisation for roxadustat in China
FDA Approvals

ABPI and NHS Are in Talks for New Medicines Scheme in the UK

8th May 2023

Latest News

News

European Medicines Agency Ends COVID-19 Prioritization Plan

13th May 2023
Drug Development

Rising Pharmaceuticals Demand Drives Tablet Coatings Market

13th May 2023
News

Connected Drug Delivery Devices To Revolutionize Healthcare

12th May 2023
Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19
Drug Development

Particle Size Distribution Real-Time Monitoring With PEACE

10th May 2023
Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity
Drug Development

Mettler-Toledo Showcases a Suite of Affordable Smart Inspection Technologies at Interpack to Boost Pharma Productivity

8th May 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In